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Cross-linking of IgE-Fc receptors of purified rat  mast  cells produces a  transient 
elevation  in  cyclic 3',5'-adenosine monophosphate  (cyclic AMP)  at  15  s,  which  is 
associated with the onset of secretion of granule constituents (1, 2). By analogy to the 
mechanism by which pharmacologic receptors are transmembrane-linked to adenylate 
cyclase (3, 4), recent studies have indicated that the IgE receptor is also linked to a 
subpopulation  of adenylate  eyclase  through  a  coupling  protein  termed  the  G/F 
protein  because  of its  biologic  activation  by  guanosine  triphosphate  (GTP)  and 
pharmacologic response to fluoride. Structural analogues of adenosine with an intact 
ribose act through a membrane R site, by a GTP-G/F protein-dependent mechanism, 
to activate the catalytic unit of adenylate cyclase and to augment simultaneously IgE- 
Fe receptor-initiated mediator release (5). Conversely, structural analogues of adeno- 
sine  with  an  intact  purine  moiety occupy an  intracellular  P  site,  possibly  at  the 
guanosine  diphosphate  (GDP)-G/F protein complex, to maintain  this  form of the 
complex,' thereby suppressing  activation  of the  catalytic  unit,  and  simultaneously 
inhibiting  IgE-Fc  receptor-initiated  granule  secretion  (5).  The  linear  relationship 
between attenuation of the IgE-Fe receptor-initiated rise in cyclic AMP and inhibition 
of mediator release by a P site agonist indicates a direct relationship between IgE-Fc 
receptor perturbation, transmembrane activation of adenylate cyclase, and granule 
secretion (5). The additional finding that dose-dependent immunologic activation of 
mast cells for histamine release was associated with progressive activation of cyclic 
AMP-dependent protein kinase isoenzymes (6) suggested that cyclic AMP represented 
a  messenger between the membrane and  cytoplasmic stages  of coupled activation- 
secretion.  Indeed,  there was  a  linear relationship  between  the  activation  of cyclic 
AMP-dependent protein kinase isoenzymes and mediator release when incremental 
amounts of a  P  site agonist  were used to suppress adenylate cyclase. Furthermore, 
differential analysis reveals activation of both the type I  and  type II cyclic AMP- 
dependent protein kinase isoenzymes with and without a P site agonist in the secretory 
response to IgE-Fc receptor perturbation. 
Materials and Methods 
Materials.  Porcine heparin, p-nitrophenyl-fl-D-2-acetamido-2-deoxyglucopyranoside,  Dc-di- 
thiothreitol (DTT),  1 ethylene glyeol-bis-(fl-aminoethylether)-N,N'-tetraacetie  acid (EGTA), to- 
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Abbrevzations used in th,~ paper: DDA, 2',5'-dideoxyadenosine;  DEAE, diethylaminoethyl; DTT, DL- 
dithiothreitol; EGTA, ethylene glycol-bis-(fl-aminocthylether)N,N'-tetraaeetic  acid; to-NH2-Cn,  to-amino- 
hexyl-agarose; GDP, guanosine diphosphate; TGD-, calcium-free  Tyrode's buffer containing 1 mg/ml 
gelatin and 1 rag/100 ml DNase; TGD, TGD- containing 1.36 mM CaC12.2H20. 
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aminohexyi-agarose (w-NH2-CB),/~-glycerolphosphate (Sigma Chemical Co., St. Louis, Mo.); 
deoxyribonuctease I (DNase) (Calbiochem-Behring Corp., American Hoechst Corp., San Diego, 
Calif.); metrizamide (Accurate Chemical & Scientific Corp., Hieksvitle, N. Y.); gelatin (Difco 
Laboratories, Detroit, Mich.); P-81 phosphocellulose chromatography paper (Whatman, Inc., 
Clifton, N. J.); adenosine 5'-triphosphate tetra (triethyl ammonium) salt, [732-P] (1,000-3,000 
Ci/mmol)  (New England Nuclear, Boston, Mass.); and 2',5'-dideoxyadenosine (DDA)  (P. L. 
Bioehemicals, Inc., Milwaukee, Wis.) were obtained from the manufacturers. Rabbit IgG anti- 
rat IgE was prepared by ammonium sulfate fractionation and DEAE ion-exchange chromatog- 
raphy (7). 
Mast Cell Purification and Activation.  Rat serosal cells were obtained by pleural and peritoneal 
lavage of 50-100 adult Sprague-Dawley rats with calcium-free Tyrode's buffer containing  1 
mg/ml  gelatin,  1 mg/100  ml  DNase  (TGD-),  and  5  mg/100  ml  heparin.  Mast  cells were 
isolated by isopyknic sedimentation at 400 g for 15 rain with 22.5%  metrizamide in TGD- at 
23°C, followed by velocity sedimentation through a continuous 3-9% metrizamide gradient in 
TGD- at 35-55 g for 12 min at 23°C. The mast cells were 97-99% pure when assessed by light 
microscopy of suspensions stained with 0.1%  toluidine blue in ethyl alcohol. Contaminating 
erythrocytes, if present, were removed by a second centrifugation through 3-9% metrizamide. 
To assess the kinetics of activation of protein kinase-mixed isoenzymes and mediator release, 
five duplicate suspensions of 10  e mast cells in  100 #1 of TGD- containing 1.36 mM CAC12.2 
H20 (TGD) were preincubated at 37°C for 5 min, and challenged with rabbit IgG anti-rat IgE 
at a final dilution of 1:25 (vol:vol) at 37°C. The reactions were terminated at 0,  15, 30, 60, or 
120 s by the addition of 150 gl iced TGD- and centrifugation at 100 g for 5 min at 4°C. The 
supernates were removed, and the cell pellets were resuspended in 250 #1 TGD- and disrupted 
by sonication at 4°C (model 350 Sonifier; Branson Sonic Power Co., Danbury, Conn. used at 
power 3, 50% pulse cycle, 5 pulses). ~8-Hexosaminidase was assayed in mast cell supernates and 
pellets by cleavage ofp-nitrophenyl-/~-n-2-acetamido-2-deoxyglucopyranoside.  The net percent 
release of~8-hexosaminidase was calculated as follows: net percent release =  [stimulated release 
minus unstimulated release/unstimulated (release plus residual)] ×  100. This measurement has 
been shown to be highly reproducible, parallels the release of histamine, and is unaffected by 
DDA in this concentration range (5, 8). Protein kinase activity was assessed in the extracted 
pellets in the absence and presence of 2 #M cyclic AMP and expressed as incorporation of S2p 
counts per minute into protamine (6). Net percent activation of cyclic AMP dependent protein 
kinase was calculated as follows: net percent activation of cyclic AMP-dependent protein kinase 
=  [activity in  unstimulated  cell  pellet  minus  activity in  stimulated cell  pellet/activity in 
unstimulated cell pellet] X  100. 
To  determine the effect of the  P  site a~onist, DDA, on  the activation of protein kinase 
isoenzymes, six duplicate suspensions of 10  ° mast cells in  100/.d of TGD were preincubated 
with 0, 50,  100, 250,  500, or 1,000 gM concentrations of DDA for 5 rain before challenge with 
anti-rat IgE at a final dilution of 1:25 (vol:vol). The reactions were terminated at 1 min by the 
addition of 100 #1 ice-cold TGD- and the net percent jS-hexosaminidase release and net percent 
activation of cyclic AMP-dependent  protein  kinase were  assessed.  Cyclic AMP-dependent 
protein kinase activity in cells exposed to DDA alone was unaffected as compared with cells 
treated with buffer. 
The net percent activation of the isoenzymes of mast cell cyclic AMP-dependent protein 
kinases was determined after their separation on o~-NH2-C6. Suspensions of 10  mast cells in  1 
ml TGD were preincubated at 37°C  for 5 rain with or without added DDA. The cells were 
challenged with IgG anti-rat IgE at a final dilution of 1:25, and the reactions were terminated 
at  1 min with  1 ml ice-cold TGD-. The mixtures were centrifuged, and the supernates were 
removed and assessed for fl-hexosaminidase. The pellets were resuspended in 500 #1 50 mM 
glycerol phosphate, pH 7.0, containing 1 mM DTT (buffer A), and disrupted by sonication as 
described above. 25-#1 samples of each replicate were further sonicated in 500 #1  1 M  NaCI, 
and 50 ~1 of this mixture was analyzed for fl-hexosaminidase. The remaining original 475 #1 of 
cell pellets sonieated in buffer A were each sedimented at 2,000 g at 4°C for 15 rain, and the 
supernate was retained; the pellets were re-extracted with 100 #1 buffer A. The combined buffer 
A  cell  extracts  from  each  replicate were  applied  to  individual  500-#1 ~0-NH2-C6 columns 
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(500 #1) to elute type I cyclic AMP-dependent protein kinase, and then with buffer A containing 
0.5 M  NaCI to elute type II. Samples of each fraction were assayed for protein kinase activity 
in the absence and in the presence of 2 ~aM cyclic AMP. Recovery from the columns was 102 
-4- 8.6% (mean :t: SEM, n ffi 8). 
Results 
Activation of Types I and II Cyclic AMP-dependent Protein Kinase.  Immunologic acti- 
vation of cyclic AMP-dependent  protein kinase  isoenzymes was maximal and pla- 
teaued  at  30  s;  release  of//-hexosaminidase  was  maximal  at  1 min.  Thus,  in  all 
experiments activation of protein kinase  was assessed at  1 rain after the addition of 
anti-IgE. 
Chromatography of cell sonieates of immunologically challenged rat mast cells on 
¢-NHz-Ce-agarose  completely  separated  type  I  from  type  II.  In  the  experiment 
depicted  in  Fig.  1,  the  net  percent  activation  (mean  ±  SEM)  of types  I  and  II 
isoenzymes was 25.1  ±  2.4 and 36.0 ±  8.2%, respectively,  and the net percent  release 
of~8-hexosaminidase was 39.8 ±  2.4% (P <  0.001). In eight preparations of rat serosal 
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Fxo.  1.  ee-Aminohexy]-agarose chromatography of rat mast cell cyclic AMP-dependent protein 
kinases with (0) and without (O) prior activation with IgG anti-rat IgE. The results depict a single 
representative experiment in which duplicate samples of cells were challenged or exposed to buffer 
alone. Assays depict the increment in the presence of cyclic AMP, as there was no cyclic AMP- 
independent protein kinase activity in the fractions. 
TABLE  I 
Immunologic Activation by Anti-lgE of Rat Mast Cell Protein Kinase 
Isoenzymes 
Mean ±  SEM 
P value*  (net %) 
~-Hexosaminidase release 
Type I  activation vs. total protein kinase in 
TGD control 
Type II activation vs. total protein kinase in 
TGD control 
Type I activation vs. type I in TGD control 
Type II activation vs. type II in TGD control 
32.0 ±  4.3  <0.001 
18.4 ±  2.6  <0.001 
8.6 ±  1.5  <0.001 
27.1  ±  3.5  <0.001 
26.6 ±  4.5  <0.001 
* Results are compared in a  two-tailed statistical analysis for n =ffi 8 determi- 
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Fxo.  2.  Comparison of net percent activation of type I cyclic AMP-dependent protein kinase vs. 
type II  isoenzyme in rat mast cells challenged with anti-IgE. The results are from seven of eight 
experiments, and data were averaged when duplicate  determinations were  carried out  with  the 
same mast cell preparation. 
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FIo.  3.  Dose-response effect of DDA on rat  mast cell  net percent fl-hexosaminidase release  (@) 
and net percent activation of cyclic AMP-dependent protein kinase (O). The results are expressed 
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FIG.  4.  Net percent release of fl-hexosaminidase as a  function of cyclic AMP-dependent protein 
kinase activation. Data are From Fig. 3 (correlation coefficient -- 0.992, n =  5, P <  0.001). 
mast cells there was no difference in the net percent activation of type I (27.1  +  3.5%, 
P  <  0.001)  and  type  II  (26.6  +  4.5%,  P  <  0.001)  isoenzymes  (Table  I).  However, 
activation of type I represented  18.4 +  2.6%  (P <  0.001)  of the total amount of cyclic 
AMP-dependent  protein kinase and activation of type II was 8.6 +  1.5% (P <  0.001) 
because there is twice as much type I as type II available in the unstimulated cell. A 
plot of the net percent of type I activated vs. the net percent of type II activated using 
seven  of eight  separate  experiments,  summarized  in  Table  I,  gives  a  straight  line 
(correlation coefficient -- 0.829,  P <  0.01), which passes through  14.4%  on the type I C.  M.  WINSLOW,  R.  A.  LEWIS,  AND  K.  F.  AUSTEN  1129 
axis  (Fig.  2),  suggesting  that  at  least  14.4%  of the  type I  protein  kinase  may be 
activated independently of type II. 
Effect of P Site Adenylate Cyclase Inhibitors on Activation of Mast Cell Cyclic AMP-dependent 
Protein Kinases.  Type I  or type II cyclic AMP-dependent protein kinase activation 
during release of mediators from the mast cell was further investigated using a P site 
inhibitor of adenylate cyclase to regulate the levels of cyclic AMP and corresponding 
activation of protein kinases. In four experiments with concentrations of DDA ranging 
from 50 to 1,000 #M, there was a dose-related inhibition of/3-hexosaminidase release 
and  suppression  of activation of cyclic AMP-dependent  protein kinase  isoenzymes 
(Fig.  3).  Net percent /3-hexosaminidase release directly correlates with  net  percent 
activation of cyclic AMP-dependent protein kinase isoenzymes, giving a straight line 
(correlation coefficient ~- 0.992, P <  0.001), which passes through the origin (Fig. 4). 
The single point of>30% activation of  cyclic AMP-dependent protein kinase obtained 
without any DDA did not fall on the line, suggesting a  possible threshold function 
between inhibition of activation of the isoenzymes and  a  decrease in the secretory 
response. 
To examine differential activation of the isoenzymes, concentrations were selected 
that have a threshold (100 #M), a moderate (250 and 500 #M), or a maximal (1,000 
#M)  inhibitory  effect on  the  activation  of cyclic AMP-dependent  protein  kinase 
isoenzymes and release of/3-hexosaminidase. Six separate experiments were conducted 
in  order to have four experimental points  for each concentration of DDA.  1 mM 
DDA diminished the net percent/3-hexosaminidase release from 35.0 ±  3.6 to 7.1 ± 
2.1%. Type I  protein kinase net percent activation was reduced from 26.8 :t: 4.2 to 
11.0 :t: 5.9% and type II from 26.1 ±  5.0 to 16.7 ±  7.3%. At a threshold dose of DDA 
(100  #M),  /3-hexosaminidase  release  was  unaffected;  there  was  a  decrease  in  net 
percent  activation of type I  protein kinase  to 23.0  ±  6.8%  and  an  increase in the 
amount of type II isoenzyme activated to 27.5 ±  6.0%. The net percent release of/3- 
hexosaminidase decreased to 21.0.+  3.2  and  14.82  ±  1.7% with  250  and  500 #M 
DDA, respectively. The net percent activation of type I cyclic AMP-dependent protein 
kinase was reduced to 19.1 ±  5.3 and  10.1 ±  4.0%, respectively. For the two doses of 
DDA, type II cyclic AMP-dependent protein kinase isoenzyme net percent activation 
fell to 22.6 ±  6.7% at 250 #M and  17.8 ±  6.8% at 500 #M. 
The  net  percent  release  of/3-hexosaminidase  and  the  specific activation  of the 
protein kinase isoenzymes for each concentration of DDA were plotted as a  percent 
relative to each function in cells exposed to immunologic challenge in the absence of 
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F1o.  5.  Net percent activation of rat mast cell cyclic AMP-dependent protein kinase isoenzymcs 
(- -  -)  type I  (F-I) and type II  (O)  and fl-hexosaminldase  release (0),  as a  function  of percent 
maximum/~-hexosaminidase release (35.0%), and corresponding protein kinase activation (type I, 
26.8%, and type II, 26.1%) with immunologic challenge in the absence of DDA. Each point is the 
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DDA. This was done to normalize the data relative to a maximal percent in order to 
allow examination of the relationship of the three parameters of cell response in six 
different cell preparations (Fig. 5). fl-Hexosaminidase release corresponded to a slope 
of 0.350, whereas the slope for activation of types I and II was 0.264. These results 
suggest that activation of both types I and II cyclic AMP-dependent protein kinase 
isoenzymes correlates with release of fl-hexosaminidase from immunologicaUy chal- 
lenged rat serosal mast cells. 
Discussion 
The  IgE  receptor-initiated  transmembrane  activation  of adenylate cyclase was 
suspected by the time relationship between the early transient rise in cyclic AMP and 
the immediately subsequent mediator release (1, 2). The quantitative nature of this 
relationship was not established until mast cells were activated by anti-IgE in the 
presence of increasing concentrations of the P  site agonist, DDA,  so as to achieve 
progressive inhibition of adenylate cyclase, and corresponding attenuation of the rise 
of cyclic AMP and of the release of secretory granule constituents (5).  The earlier 
finding that incremental activation of rat mast cells by anti-light chain antiserum 
and  histamine release  was  associated  with  a  progressive  decline  in  cellular cyclic 
AMP-dependent protein kinase holoenzyme did not reveal whether the activation of 
the cyclic AMP-dependent protein kinase was essential for the secretory reaction to 
proceed or represented a negative feedback regulatory event (6). The linear relation- 
ship between the net percent/~-hexosaminidase release and the net percent activation 
of cyclic AMP-dependent protein kinase isoenzymes, when the IgE-dependent acti- 
vation  of adenylate cyclase is  suppressed  by  incremental concentrations of DDA, 
indicated  a  direct  relationship  between  the  activation  of cyclic  AMP-dependent 
protein kinase and the secretory response (Figs. 3 and 4). Assessment of residual cyclic 
AMP-dependent protein  kinase activity in cell extracts was used to define percent 
activation of the combined isoenzymes after immunologic challenge because recovery 
of free catalytic subunit is incomplete in physiologic buffer. Attempts to recover free 
catalytic subunit activity using available techniques,  such  as  high salt  extraction, 
result  in  both  partial  activation  of the  holoenzyme and  inactivation  of the  free 
catalytic suhunit (9-11).  Measurement of holoenzyme depletion to assess activation 
of combined or chromatographically separated cyclic AMP-dependent protein kinase 
isoenzymes has been reliably employed in other cell systems (12-14). 
The rat mast cell contains cyclic AMP-dependent protein kinase isoenzymes types 
I and II that can be separated without overlap (Fig.  1) by w-NH2-C6 chromatography 
(6,  14-16).  Activation of the individual isoenzymes was measured by residual cyclic 
AMP-dependent types I  and II activity after chromatographic separation, wherein 
the recovery of the isoenzymes is  100% of the cyclic AMP-dependent protein kinase 
holoenzyme activity in the cell extracts applied for separation. In eight consecutive 
experiments in which purified rat mast cells were activated with anti-IgE, the mean 
net fl-hexosaminidase release of 32% was accompanied by a net percent activation of 
cyclic AMP-dependent protein kinase that was 27% for both isoenzymes (Table I). As 
the type I protein kinase was twice as abundant as the type II, the percent activation 
relative to the total holoenzyme pool  was twice as great  for type I. Although the 
activation of the cyclic AMP-dependent isoenzymes during coupled activation and 
secretion  was  related  in  a  linear  fashion, the  extrapolated  intercept  implied  that C.  M.  WINSLOW,  R.  A.  LEWIS,  AND  K.  F.  AUSTEN  1131 
almost 15% of the type I could be activated without type II (Fig. 2). The differential 
activation  of the  isoenzymes apparent  in  Fig.  2  raises  the  question  of different 
functions. Opposing biological effects have been implied in the literature for selective 
activation of cytoplasmic isoenzymes (14), and there is cell cycle-specific expression of 
types I and II cyclic AMP-dependent protein kinases in metabolically synchronized 
Chinese hamster ovary cells (17). There is also evidence that particulate type II, but 
not cytosolic type I, cyclic AMP-dependent protein kinase in rat myocardium responds 
to  the  appropriate  agonist,  with  activation  of phosphorylase  and  an  increase  in 
myocardial contractibility (18). 
The IgE receptor-initiated activation of adenylate cyclase was suppressed with the 
P  site agonist DDA to determine whether the corresponding inhibition of mediator 
release could be related to a  preferential failure to activate one of the isoenzymes. 
There was parallel suppression of activation of both isoenzymes (Fig. 5).  Maximal 
activation of either isoenzyme was 25-30%, and release of preformed mediators was 
directly related to activation of the two isoenzymes. This finding contrasts with the 
dose-related  effects of theophylline in  raising cyclic AMP  and  yielding a  percent 
inhibition  of mediator  release  and  percent  activation  of cyclic  AMP-dependent 
protein kinase type I  with superimposable slopes progressing to  100%. The percent 
activation of type II cyclic AMP-dependent protein kinase was approximately half 
that of type I at each theophylline concentration and plateaued at -50% when type 
I  activation was at  100% and mediator release was completely suppressed  (19,  20). 
The down-regulating effect of theophylline may result either from the depletion of 
cyclic AMP-dependent protein kinase essential for the integrated release response or 
from the phosphorylation by the protein kinase of an inhibitory protein. The dose- 
related effects of an adenylate cyclase P site inhibitor on activation of cyclic AMP- 
dependent  protein  kinases  and  mediator  release  establish  the  second  messenger 
function of cyclic AMP in mast cell-coupled activation and secretion, linking extra- 
cellular IgE-Fc receptor perturbation with membrane-associated adenylate cyclase, 
and the intracellular events that lead to the response to stimulus, i.e., degranulation. 
Summary 
Stereo-specific perturbation of the IgE-receptor (shown in previous studies) produces 
a  monophasic rise in cyclic AMP that peaks at  15 s and a  depletion of cyclic AMP- 
dependent protein kinase that plateaus at 30-60  s. The previously observed linear 
relationship between the attenuation in the monophasic rise in cyclic AMP and the 
quantity of mediator release  in  the presence of incremental concentrations of the 
adenosine analogue 2',5'-dideoxyadenosine, DDA, which is known to inhibit adenylate 
cyclase, indicated a direct relationship between receptor perturbation, transmembrane 
activation of adenylate cyclase, and granule secretion. The role of cyclic AMP as a 
second  messenger  in  this  sequence  is  now  apparent  from  the  linear  relationship 
between  net  percent  mediator release  and  net  percent  activation of cyclic AMP- 
dependent  protein  kinase  isoenzyme when  IgE-dependent  activation of adenylate 
cyclase is suppressed  by incremental quantities of DDA.  There was a  comparable 
percent  activation of both types I  and II mast cell cyclic AMP-dependent protein 
kinase isoenzymes with anti-IgE-induced activation and secretion, and there was a 
parallel suppression of the activation of both  isoenzymes in the presence of DDA. 
Although these studies firmly link the activation of  cytoplasmic cyclic AMP-dependent 1132  MEDIATOR  RELEASE  AND CYCLIC  AMP-DEPENDENT  PROTEIN  KINASE 
protein kinase to  the IgE receptor-initiated transmembrane  activation of adenylate 
cyclase, they do not discriminate among the functions of the two isoenzymes. 
Received  for publication 21 May 1981. 
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